Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab in Resectable Esophageal Squamous Cell Carcinoma
NCT05213312Phase 3Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2022
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nivolumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Pathological Complete Response rate up to 12 months. Status: unknown.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05213312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05213312.